More problems for BioNTech & Roche’s neoantigen shot
Autogene cevumeran goes on hold in adjuvant bladder cancer.
Autogene cevumeran goes on hold in adjuvant bladder cancer.
Multispecifics newly into the clinic include Car-Ts from Essen and Unicar.
PD-(L)1 x VEGF bispecifics prove a big draw.
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
Some big deals in the second quarter have raised hopes that takeouts are back.